These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Triplet CFTR modulators: future prospects for treatment of cystic fibrosis. Chaudary N Ther Clin Risk Manag; 2018; 14():2375-2383. PubMed ID: 30584312 [TBL] [Abstract][Full Text] [Related]
24. Modeling Cystic Fibrosis Using Pluripotent Stem Cell-Derived Human Pancreatic Ductal Epithelial Cells. Simsek S; Zhou T; Robinson CL; Tsai SY; Crespo M; Amin S; Lin X; Hon J; Evans T; Chen S Stem Cells Transl Med; 2016 May; 5(5):572-9. PubMed ID: 27034411 [TBL] [Abstract][Full Text] [Related]
25. R560S: A class II CFTR mutation that is not rescued by current modulators. Awatade NT; Ramalho S; Silva IAL; Felício V; Botelho HM; de Poel E; Vonk A; Beekman JM; Farinha CM; Amaral MD J Cyst Fibros; 2019 Mar; 18(2):182-189. PubMed ID: 30030066 [TBL] [Abstract][Full Text] [Related]
26. Extent of rescue of F508del-CFTR function by VX-809 and VX-770 in human nasal epithelial cells correlates with SNP rs7512462 in SLC26A9 gene in F508del/F508del Cystic Fibrosis patients. Kmit A; Marson FAL; Pereira SV; Vinagre AM; Leite GS; Servidoni MF; Ribeiro JD; Ribeiro AF; Bertuzzo CS; Amaral MD Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1323-1331. PubMed ID: 30716472 [TBL] [Abstract][Full Text] [Related]
27. β2-Adrenergic receptor agonists activate CFTR in intestinal organoids and subjects with cystic fibrosis. Vijftigschild LA; Berkers G; Dekkers JF; Zomer-van Ommen DD; Matthes E; Kruisselbrink E; Vonk A; Hensen CE; Heida-Michel S; Geerdink M; Janssens HM; van de Graaf EA; Bronsveld I; de Winter-de Groot KM; Majoor CJ; Heijerman HG; de Jonge HR; Hanrahan JW; van der Ent CK; Beekman JM Eur Respir J; 2016 Sep; 48(3):768-79. PubMed ID: 27471203 [TBL] [Abstract][Full Text] [Related]
28. The major cystic fibrosis causing mutation exhibits defective propensity for phosphorylation. Pasyk S; Molinski S; Ahmadi S; Ramjeesingh M; Huan LJ; Chin S; Du K; Yeger H; Taylor P; Moran MF; Bear CE Proteomics; 2015 Jan; 15(2-3):447-61. PubMed ID: 25330774 [TBL] [Abstract][Full Text] [Related]
29. Enhanced F508del-CFTR channel activity ameliorates bone pathology in murine cystic fibrosis. Le Henaff C; Haÿ E; Velard F; Marty C; Tabary O; Marie PJ; Jacquot JP Am J Pathol; 2014 Apr; 184(4):1132-1141. PubMed ID: 24529904 [TBL] [Abstract][Full Text] [Related]
30. High-throughput functional assay in cystic fibrosis patient-derived organoids allows drug repurposing. Spelier S; de Poel E; Ithakisiou GN; Suen SWF; Hagemeijer MC; Muilwijk D; Vonk AM; Brunsveld JE; Kruisselbrink E; van der Ent CK; Beekman JM ERJ Open Res; 2023 Jan; 9(1):. PubMed ID: 36726369 [TBL] [Abstract][Full Text] [Related]
31. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment. Pettit RS Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718 [TBL] [Abstract][Full Text] [Related]
32. Targeted correction and restored function of the CFTR gene in cystic fibrosis induced pluripotent stem cells. Crane AM; Kramer P; Bui JH; Chung WJ; Li XS; Gonzalez-Garay ML; Hawkins F; Liao W; Mora D; Choi S; Wang J; Sun HC; Paschon DE; Guschin DY; Gregory PD; Kotton DN; Holmes MC; Sorscher EJ; Davis BR Stem Cell Reports; 2015 Apr; 4(4):569-77. PubMed ID: 25772471 [TBL] [Abstract][Full Text] [Related]
33. The investigational Cystic Fibrosis drug Trimethylangelicin directly modulates CFTR by stabilizing the first membrane-spanning domain. Laselva O; Molinski S; Casavola V; Bear CE Biochem Pharmacol; 2016 Nov; 119():85-92. PubMed ID: 27614011 [TBL] [Abstract][Full Text] [Related]
34. An unexpected effect of TNF-α on F508del-CFTR maturation and function. Bitam S; Pranke I; Hollenhorst M; Servel N; Moquereau C; Tondelier D; Hatton A; Urbach V; Sermet-Gaudelus I; Hinzpeter A; Edelman A F1000Res; 2015; 4():218. PubMed ID: 26594334 [TBL] [Abstract][Full Text] [Related]
35. Impact of the cystic fibrosis mutation F508del-CFTR on renal cyst formation and growth. Li H; Yang W; Mendes F; Amaral MD; Sheppard DN Am J Physiol Renal Physiol; 2012 Oct; 303(8):F1176-86. PubMed ID: 22874761 [TBL] [Abstract][Full Text] [Related]
36. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review. Yang H; Ma T Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311 [TBL] [Abstract][Full Text] [Related]
37. Prime editing-mediated correction of the CFTR W1282X mutation in iPSCs and derived airway epithelial cells. Li C; Liu Z; Anderson J; Liu Z; Tang L; Li Y; Peng N; Chen J; Liu X; Fu L; Townes TM; Rowe SM; Bedwell DM; Guimbellot J; Zhao R PLoS One; 2023; 18(11):e0295009. PubMed ID: 38019847 [TBL] [Abstract][Full Text] [Related]
38. Optimal correction of distinct CFTR folding mutants in rectal cystic fibrosis organoids. Dekkers JF; Gogorza Gondra RA; Kruisselbrink E; Vonk AM; Janssens HM; de Winter-de Groot KM; van der Ent CK; Beekman JM Eur Respir J; 2016 Aug; 48(2):451-8. PubMed ID: 27103391 [TBL] [Abstract][Full Text] [Related]